197 related articles for article (PubMed ID: 19262954)
1. Evolution of Abeta42 and Abeta40 levels and Abeta42/Abeta40 ratio in plasma during progression of Alzheimer's disease: a multicenter assessment.
Blennow K; De Meyer G; Hansson O; Minthon L; Wallin A; Zetterberg H; Lewczuk P; Vanderstichele H; Vanmechelen E; Kornhuber J; Wiltfang J; ; Heuser I; Maier W; Luckhaus C; Rüther E; Hüll M; Jahn H; Gertz HJ; Frölich L; Hampel H; Pernetzki R
J Nutr Health Aging; 2009 Mar; 13(3):205-8. PubMed ID: 19262954
[TBL] [Abstract][Full Text] [Related]
2. The relationship of plasma Aβ levels to dementia in aging individuals with mild cognitive impairment.
Fei M; Jianghua W; Rujuan M; Wei Z; Qian W
J Neurol Sci; 2011 Jun; 305(1-2):92-6. PubMed ID: 21440911
[TBL] [Abstract][Full Text] [Related]
3. A two-step immunoassay for the simultaneous assessment of Aβ38, Aβ40 and Aβ42 in human blood plasma supports the Aβ42/Aβ40 ratio as a promising biomarker candidate of Alzheimer's disease.
Shahpasand-Kroner H; Klafki HW; Bauer C; Schuchhardt J; Hüttenrauch M; Stazi M; Bouter C; Wirths O; Vogelgsang J; Wiltfang J
Alzheimers Res Ther; 2018 Dec; 10(1):121. PubMed ID: 30526652
[TBL] [Abstract][Full Text] [Related]
4. Combining plasma Aβ and p-tau217 improves detection of brain amyloid in non-demented elderly.
Niimi Y; Janelidze S; Sato K; Tomita N; Tsukamoto T; Kato T; Yoshiyama K; Kowa H; Iwata A; Ihara R; Suzuki K; Kasuga K; Ikeuchi T; Ishii K; Ito K; Nakamura A; Senda M; Day TA; Burnham SC; Iaccarino L; Pontecorvo MJ; Hansson O; Iwatsubo T
Alzheimers Res Ther; 2024 May; 16(1):115. PubMed ID: 38778353
[TBL] [Abstract][Full Text] [Related]
5. Multiplex immunoassay measurement of amyloid-β
Vogelgsang J; Shahpasand-Kroner H; Vogelgsang R; Streit F; Vukovich R; Wiltfang J
Exp Brain Res; 2018 May; 236(5):1241-1250. PubMed ID: 29480353
[TBL] [Abstract][Full Text] [Related]
6. Elevation of the Plasma Aβ40/Aβ42 Ratio as a Diagnostic Marker of Sporadic Early-Onset Alzheimer's Disease.
Kim HJ; Park KW; Kim TE; Im JY; Shin HS; Kim S; Lee DH; Ye BS; Kim JH; Kim EJ; Park KH; Han HJ; Jeong JH; Choi SH; Park SA
J Alzheimers Dis; 2015; 48(4):1043-50. PubMed ID: 26444752
[TBL] [Abstract][Full Text] [Related]
7. Alzheimer's cerebrospinal biomarkers from Lumipulse fully automated immunoassay: concordance with amyloid-beta PET and manual immunoassay in Koreans : CSF AD biomarkers measured by Lumipulse in Koreans.
Moon S; Kim S; Mankhong S; Choi SH; Vandijck M; Kostanjevecki V; Jeong JH; Yoon SJ; Park KW; Kim EJ; Yoon B; Kim HJ; Jang JW; Hong JY; Park DH; Shaw LM; Kang JH
Alzheimers Res Ther; 2021 Jan; 13(1):22. PubMed ID: 33436035
[TBL] [Abstract][Full Text] [Related]
8. Impaired lipoprotein receptor-mediated peripheral binding of plasma amyloid-β is an early biomarker for mild cognitive impairment preceding Alzheimer's disease.
Sagare AP; Deane R; Zetterberg H; Wallin A; Blennow K; Zlokovic BV
J Alzheimers Dis; 2011; 24(1):25-34. PubMed ID: 21157031
[TBL] [Abstract][Full Text] [Related]
9. Amyloid-β peptides in cerebrospinal fluid of patients with dementia with Lewy bodies.
van Steenoven I; van der Flier WM; Scheltens P; Teunissen CE; Lemstra AW
Alzheimers Res Ther; 2019 Oct; 11(1):83. PubMed ID: 31601267
[TBL] [Abstract][Full Text] [Related]
10. Plasma and cerebrospinal fluid levels of amyloid beta proteins 1-40 and 1-42 in Alzheimer disease.
Mehta PD; Pirttilä T; Mehta SP; Sersen EA; Aisen PS; Wisniewski HM
Arch Neurol; 2000 Jan; 57(1):100-5. PubMed ID: 10634455
[TBL] [Abstract][Full Text] [Related]
11. The normal equilibrium between CSF and plasma amyloid beta levels is disrupted in Alzheimer's disease.
Giedraitis V; Sundelöf J; Irizarry MC; Gårevik N; Hyman BT; Wahlund LO; Ingelsson M; Lannfelt L
Neurosci Lett; 2007 Nov; 427(3):127-31. PubMed ID: 17936506
[TBL] [Abstract][Full Text] [Related]
12. Ultrasensitive Detection of Plasma Amyloid-β as a Biomarker for Cognitively Normal Elderly Individuals at Risk of Alzheimer's Disease.
Chatterjee P; Elmi M; Goozee K; Shah T; Sohrabi HR; Dias CB; Pedrini S; Shen K; Asih PR; Dave P; Taddei K; Vanderstichele H; Zetterberg H; Blennow K; Martins RN
J Alzheimers Dis; 2019; 71(3):775-783. PubMed ID: 31424403
[TBL] [Abstract][Full Text] [Related]
13. Influence of kidney function and CSF/serum albumin ratio on plasma Aβ42 and Aβ40 levels measured on a fully automated platform in patients with Alzheimer's disease.
Verde F; Milone I; Dubini A; Colombrita C; Perego A; Solca F; Maranzano A; Ciusani E; Poletti B; Ratti A; Torresani E; Silani V; Ticozzi N
Neurol Sci; 2023 Sep; 44(9):3287-3290. PubMed ID: 37284933
[TBL] [Abstract][Full Text] [Related]
14. Chemically treated plasma Aβ is a potential blood-based biomarker for screening cerebral amyloid deposition.
Park JC; Han SH; Cho HJ; Byun MS; Yi D; Choe YM; Kang S; Jung ES; Won SJ; Kim EH; Kim YK; Lee DY; Mook-Jung I
Alzheimers Res Ther; 2017 Mar; 9(1):20. PubMed ID: 28330509
[TBL] [Abstract][Full Text] [Related]
15. Plasma Amyloid and in vivo Brain Amyloid in Late Middle-Aged Hispanics.
Rippon B; Palta P; Tahmi M; Sherwood G; Soto L; Cespedes S; Mesen Y; He H; Laing K; Moreno H; Teresi J; Razlighi Q; Brickman AM; Zetterberg H; Luchsinger JA
J Alzheimers Dis; 2022; 87(3):1229-1238. PubMed ID: 35466933
[TBL] [Abstract][Full Text] [Related]
16. Plasma Abeta42 and Abeta40 as markers of cognitive change in follow-up: a prospective, longitudinal, population-based cohort study.
Seppälä TT; Herukka SK; Hänninen T; Tervo S; Hallikainen M; Soininen H; Pirttilä T
J Neurol Neurosurg Psychiatry; 2010 Oct; 81(10):1123-7. PubMed ID: 20478847
[TBL] [Abstract][Full Text] [Related]
17. New plasma LC-MS/MS assays for the quantitation of beta-amyloid peptides and identification of apolipoprotein E proteoforms for Alzheimer's disease risk assessment.
Weber DM; Kim JC; Goldman SM; Clarke NJ; Racke MK
J Investig Med; 2024 Jun; 72(5):465-474. PubMed ID: 38548482
[TBL] [Abstract][Full Text] [Related]
18. Plasma concentrations of free amyloid β cannot predict the development of Alzheimer's disease.
Lövheim H; Elgh F; Johansson A; Zetterberg H; Blennow K; Hallmans G; Eriksson S
Alzheimers Dement; 2017 Jul; 13(7):778-782. PubMed ID: 28073031
[TBL] [Abstract][Full Text] [Related]
19. Plasma Amyloid Concentration in Alzheimer's Disease: Performance of a High-Throughput Amyloid Assay in Distinguishing Alzheimer's Disease Cases from Controls.
Feinkohl I; Schipke CG; Kruppa J; Menne F; Winterer G; Pischon T; Peters O
J Alzheimers Dis; 2020; 74(4):1285-1294. PubMed ID: 32176645
[TBL] [Abstract][Full Text] [Related]
20. Combination of gut microbiota and plasma amyloid-β as a potential index for identifying preclinical Alzheimer's disease: a cross-sectional analysis from the SILCODE study.
Sheng C; Yang K; He B; Du W; Cai Y; Han Y
Alzheimers Res Ther; 2022 Feb; 14(1):35. PubMed ID: 35164860
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
